CSBR (Champions Oncology) Cyclically Adjusted Revenue per Share: $3.37 (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
61 GF Score
Price $5.82
GF Value $6.65
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Cyclically Adjusted Revenue per Share?

Champions Oncology CSBR -2.18% 61 Cyclically Adjusted Revenue per Share is $3.37 as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 61/100 and a GF Value™ of $6.65 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Champions Oncology's adjusted revenue per share for the three months ended in Jan. 2026 was $1.192. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.37 for the trailing ten years ended in Jan. 2026.

During the past 12 months, Champions Oncology's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Champions Oncology was 10.60% per year. The lowest was -9.20% per year. And the median was 3.60% per year.

As of today (2026-07-11), Champions Oncology's current stock price is $5.82. Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2026 was $3.37. Champions Oncology's Cyclically Adjusted PS Ratio of today is 1.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Champions Oncology was 9.10. The lowest was 0.84. And the median was 2.49.


Champions Oncology  (NAS:CSBR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Champions Oncology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.82/3.37
=1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Champions Oncology was 9.10. The lowest was 0.84. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Champions Oncology Cyclically Adjusted Revenue per Share Related Terms


Champions Oncology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Cyclically Adjusted Revenue per Share Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.10 2.39 2.66 2.84 3.13

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 3.13 3.21 3.28 3.37

CSBR vs SEER, RLYB, FBIO: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted PS Ratio falls into.


CSBR
61GF Score
Champions Oncology Inc CSBR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Champions Oncology's adjusted Revenue per Share data for the three months ended in Jan. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jan. 2026 (Change)*Current CPI (Jan. 2026)
=1.192/325.2520*325.2520
=1.192

Current CPI (Jan. 2026) = 325.2520.

Champions Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201604 0.327 239.261 0.445
201607 0.373 240.628 0.504
201610 0.406 241.729 0.546
201701 0.325 242.839 0.435
201704 0.301 244.524 0.400
201707 0.458 244.786 0.609
201710 0.474 246.663 0.625
201801 0.462 247.867 0.606
201804 0.447 250.546 0.580
201807 0.493 252.006 0.636
201810 0.477 252.885 0.614
201901 0.559 251.712 0.722
201904 0.527 255.548 0.671
201907 0.580 256.571 0.735
201910 0.588 257.346 0.743
202001 0.659 257.971 0.831
202004 0.687 256.389 0.872
202007 0.671 259.101 0.842
202010 0.672 260.388 0.839
202101 0.745 261.582 0.926
202104 0.716 267.054 0.872
202107 0.840 273.003 1.001
202110 0.810 276.589 0.953
202201 0.917 281.148 1.061
202204 0.913 289.109 1.027
202207 1.016 296.276 1.115
202210 1.056 298.012 1.153
202301 0.942 299.170 1.024
202304 0.963 303.363 1.032
202307 0.930 305.691 0.990
202310 0.857 307.671 0.906
202401 0.884 308.417 0.932
202404 1.031 313.548 1.069
202407 1.001 314.540 1.035
202410 0.962 315.664 0.991
202501 1.186 317.671 1.214
202504 0.842 320.795 0.854
202507 1.015 323.048 1.022
202510 1.040 0.000
202601 1.192 325.252 1.192

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $3.37 mean?
Champions Oncology (CSBR) has a Cyclically Adjusted Revenue per Share of $3.37 as of Jan. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Cyclically Adjusted Revenue per Share too high?
Champions Oncology's current Cyclically Adjusted Revenue per Share is $3.37. Overall, Champions Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Cyclically Adjusted Revenue per Share compare to SEER and RLYB?
Champions Oncology's Cyclically Adjusted Revenue per Share of $3.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Champions Oncology and its competitors. Champions Oncology's current Cyclically Adjusted Revenue per Share is $3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.65, compared to a current price of $5.82 — trading 12.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $3.37. Champions Oncology's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Cyclically Adjusted Revenue per Share is $3.37 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $5.82 is trading 12.5% below its estimated GF Value™ of $6.65. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • Cyclically Adjusted Revenue per Share: $3.37
  • GF Value™: $6.65 vs. price of $5.82 (12.5% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score

Get the complete analysis for CSBR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.82
Price
$6.65
GF Value